Reply to Pagnoni et al. Clarifying the Clinical Utility of NTAR/RGR for PAH and CTEPH. Comment on “Iancu et al. Evaluating NT-proBNP-to-Albumin (NTAR) and RDW-to-eGFR (RGR) Ratios as Biomarkers for Predicting Hospitalization Duration and Mortality in Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Diagnostics 2025, 15, 2126”

Key Result

The study highlights the clinical relevance of NTAR/RGR ratios as potential biomarkers for predicting outcomes in PAH and CTEPH patients.

Key Points

• This commentary addresses the effectiveness of NT-proBNP-to-Albumin and RDW-to-eGFR ratios as biomarkers in PAH and CTEPH.
• Analysis of existing literature on NTAR and RGR as biomarkers.
• Discussion of clinical implications for PAH and CTEPH management.
• Explore relationships between hospitalization duration, mortality, and biomarker ratios.
• Emphasizes need for further validation of NTAR/RGR ratios in clinical settings.
• Highlights potential for improved patient management through better biomarker understanding.
• Suggests re-evaluation of current guidelines regarding biomarker application.